Cargando…

Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide

RAS oncoproteins are molecular switches associated with critical signaling pathways that regulate cell proliferation and differentiation. Mutations in the RAS family, mainly in the KRAS isoform, are responsible for some of the deadliest cancers, which has made this protein a major target in biomedic...

Descripción completa

Detalles Bibliográficos
Autores principales: Learte-Aymamí, Soraya, Martin-Malpartida, Pau, Roldán-Martín, Lorena, Sciortino, Giuseppe, Couceiro, José R., Maréchal, Jean-Didier, Macias, Maria J., Mascareñas, José L., Vázquez, M. Eugenio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814687/
https://www.ncbi.nlm.nih.gov/pubmed/36697641
http://dx.doi.org/10.1038/s42004-022-00691-7
_version_ 1784864191242305536
author Learte-Aymamí, Soraya
Martin-Malpartida, Pau
Roldán-Martín, Lorena
Sciortino, Giuseppe
Couceiro, José R.
Maréchal, Jean-Didier
Macias, Maria J.
Mascareñas, José L.
Vázquez, M. Eugenio
author_facet Learte-Aymamí, Soraya
Martin-Malpartida, Pau
Roldán-Martín, Lorena
Sciortino, Giuseppe
Couceiro, José R.
Maréchal, Jean-Didier
Macias, Maria J.
Mascareñas, José L.
Vázquez, M. Eugenio
author_sort Learte-Aymamí, Soraya
collection PubMed
description RAS oncoproteins are molecular switches associated with critical signaling pathways that regulate cell proliferation and differentiation. Mutations in the RAS family, mainly in the KRAS isoform, are responsible for some of the deadliest cancers, which has made this protein a major target in biomedical research. Here we demonstrate that a designed bis-histidine peptide derived from the αH helix of the cofactor SOS1 binds to KRAS with high affinity upon coordination to Pd(II). NMR spectroscopy and MD studies demonstrate that Pd(II) has a nucleating effect that facilitates the access to the bioactive α-helical conformation. The binding can be suppressed by an external metal chelator and recovered again by the addition of more Pd(II), making this system the first switchable KRAS binder, and demonstrates that folding-upon-binding mechanisms can operate in metal-nucleated peptides. In vitro experiments show that the metallopeptide can efficiently internalize into living cells and inhibit the MAPK kinase cascade.
format Online
Article
Text
id pubmed-9814687
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-98146872023-01-10 Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide Learte-Aymamí, Soraya Martin-Malpartida, Pau Roldán-Martín, Lorena Sciortino, Giuseppe Couceiro, José R. Maréchal, Jean-Didier Macias, Maria J. Mascareñas, José L. Vázquez, M. Eugenio Commun Chem Article RAS oncoproteins are molecular switches associated with critical signaling pathways that regulate cell proliferation and differentiation. Mutations in the RAS family, mainly in the KRAS isoform, are responsible for some of the deadliest cancers, which has made this protein a major target in biomedical research. Here we demonstrate that a designed bis-histidine peptide derived from the αH helix of the cofactor SOS1 binds to KRAS with high affinity upon coordination to Pd(II). NMR spectroscopy and MD studies demonstrate that Pd(II) has a nucleating effect that facilitates the access to the bioactive α-helical conformation. The binding can be suppressed by an external metal chelator and recovered again by the addition of more Pd(II), making this system the first switchable KRAS binder, and demonstrates that folding-upon-binding mechanisms can operate in metal-nucleated peptides. In vitro experiments show that the metallopeptide can efficiently internalize into living cells and inhibit the MAPK kinase cascade. Nature Publishing Group UK 2022-06-23 /pmc/articles/PMC9814687/ /pubmed/36697641 http://dx.doi.org/10.1038/s42004-022-00691-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Learte-Aymamí, Soraya
Martin-Malpartida, Pau
Roldán-Martín, Lorena
Sciortino, Giuseppe
Couceiro, José R.
Maréchal, Jean-Didier
Macias, Maria J.
Mascareñas, José L.
Vázquez, M. Eugenio
Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title_full Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title_fullStr Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title_full_unstemmed Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title_short Controlling oncogenic KRAS signaling pathways with a Palladium-responsive peptide
title_sort controlling oncogenic kras signaling pathways with a palladium-responsive peptide
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9814687/
https://www.ncbi.nlm.nih.gov/pubmed/36697641
http://dx.doi.org/10.1038/s42004-022-00691-7
work_keys_str_mv AT learteaymamisoraya controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT martinmalpartidapau controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT roldanmartinlorena controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT sciortinogiuseppe controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT couceirojoser controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT marechaljeandidier controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT maciasmariaj controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT mascarenasjosel controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide
AT vazquezmeugenio controllingoncogenickrassignalingpathwayswithapalladiumresponsivepeptide